Zobrazeno 1 - 10
of 11
pro vyhledávání: '"MICHELLE NEWELL"'
Autor:
Thomas H Julian, Nicholas Glascow, A Dylan Fisher Barry, Tobias Moll, Calum Harvey, Yann C Klimentidis, Michelle Newell, Sai Zhang, Michael P Snyder, Johnathan Cooper-Knock, Pamela J Shaw
Publikováno v:
EBioMedicine, Vol 68, Iss , Pp 103397- (2021)
Background: Amyotrophic lateral sclerosis (ALS) is a universally fatal neurodegenerative disease. ALS is determined by gene-environment interactions and improved understanding of these interactions may lead to effective personalised medicine. The rol
Externí odkaz:
https://doaj.org/article/b14f3c3d161c4cbdb4b00a743b2e8d20
Autor:
Peter D. Reaven, Michelle Newell, Salvador Rivas, Xinkai Zhou, Gregory J. Norman, Jin J. Zhou
Publikováno v:
Diabetes Care. 46:854-863
OBJECTIVETo determine the benefit of starting continuous glucose monitoring (CGM) in adult-onset type 1 diabetes (T1D) and type 2 diabetes (T2D) with regard to longer-term glucose control and serious clinical events.RESEARCH DESIGN AND METHODSA retro
Autor:
Alexis C. Wood, Amit Arora, Michelle Newell, Victoria L. Bland, Jin Zhou, Nicola Pirastu, Jose M. Ordovas, Yann C. Klimentidis
Publikováno v:
Wood, A C, Arora, A, Newell, M, Bland, V L, Zhou, J, Pirastu, N, Ordovas, J M & Klimentidis, Y C 2022, ' Identification of genetic loci simultaneously associated with multiple cardiometabolic traits ', Nutrition, Metabolism and Cardiovascular Diseases, vol. 32, no. 4, pp. 1027-1034 . https://doi.org/10.1016/j.numecd.2022.01.002
Nutr Metab Cardiovasc Dis
Nutr Metab Cardiovasc Dis
Background and AimsCardiometabolic disorders (CMD) arise from a constellation of features such as increased adiposity, hyperlipidemia, hypertension and compromised glucose control. Many genetic loci have shown associations with individual CMD-related
Autor:
Jin J. Zhou, Gregory J. Norman, Xinkai Zhou, Salvador Rivas, Michelle Newell, Peter D. Reaven
Objective: To determine the benefit of starting continuous glucose monitoring (CGM) in adult-onset type 1 diabetes and type 2 diabetes (T1D; T2D) on longer-term glucose control and serious clinical events. Research Design and Methods: A retrospective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78f46fe58416026d21f6baf4183a3cbd
https://doi.org/10.2337/figshare.21960560
https://doi.org/10.2337/figshare.21960560
Publikováno v:
Diabetes. 71
There is increasing recognition that older onset type 1 diabetes (T1D) is not uncommon. Although CGM use is rising dramatically among those with T1D, little is known regarding its use and benefits within this older T1D population. To address these qu
Publikováno v:
Diabetes. 71
Use of CGM in T2D is rising rapidly, yet little is known regarding its effects on glucose management in the VHA. We thus identified new CGM users (new CGM sensor prescriptions for T2D on insulin) and non-users (T2D receiving glucose strips) during th
Autor:
Amit Arora, Alexis C. Wood, Michelle Newell, Benjamin J. Renquist, Jose M. Ordovas, Jin Zhou, Yann C. Klimentidis
Publikováno v:
Diabetes
Although hyperlipidemia is traditionally considered a risk factor for type 2 diabetes (T2D), evidence has emerged from statin trials and candidate gene investigations suggesting that lower LDL cholesterol (LDL-C) increases T2D risk. We thus sought to
Autor:
Sai Zhang, Pamela J. Shaw, A Dylan Fisher Barry, Michael Snyder, Thomas Julian, Johnathan Cooper-Knock, Tobias Moll, Calum Harvey, Yann C. Klimentidis, Nicholas Glascow, Michelle Newell
Publikováno v:
EBioMedicine
EBioMedicine, Vol 68, Iss, Pp 103397-(2021)
EBioMedicine, Vol 68, Iss, Pp 103397-(2021)
BackgroundAmyotrophic lateral sclerosis (ALS) is a universally fatal neurodegenerative disease. ALS is determined by gene-environment interactions and improved understanding of these interactions may lead to effective personalised medicine. The role
Autor:
Alexis C. Wood, Benjamin J. Renquist, Jose M. Ordovas, Jin Zhou, Michelle Newell, Amit Arora, Yann C. Klimentidis, Ada Admin
Although hyperlipidemia is traditionally considered a risk factor for type-2 diabetes (T2D), evidence has emerged from statin trials and candidate gene investigations suggesting that lower LDL-C increases T2D risk. We thus sought to more comprehensiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acb86d70ccf09b2661250d9f15f291a5
https://doi.org/10.2337/figshare.12389273.v1
https://doi.org/10.2337/figshare.12389273.v1
Autor:
Jose M. Ordovas, Michelle Newell, Jin Zhou, Amit Arora, Alexis C. Wood, Benjamin J. Renquist, Yann C. Klimentidis
Although hyperlipidemia is traditionally considered a risk factor for type-2 diabetes (T2D), evidence has emerged from statin trials and candidate gene investigations suggesting that lower LDL-C increases T2D risk. We thus sought to comprehensively e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c5210b30302dd8cc65b1bfa24b6ccd7